Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (1-10 of 401) with videos related to

Pageof 41
Sort By:
Postgraduate Medical Journal|December 22, 2011
Republished education in heart: New P2Y₁₂ inhibitorsRobert F Storey
European Heart Journal|May 7, 2015
More transparency for a therapeutic window in platelet P2Y12 inhibition?Robert F Storey
Clinical Medicine (London, England)|June 4, 2014
Beware the normal angiogramRobert F Storey
European Heart Journal|October 21, 2020
The long journey of individualizing antiplatelet therapy after acute coronary syndromesRobert F Storey
Circulation|February 20, 2024
Antiplatelet Therapy After PCI: The Art and Science of De-EscalationRobert F Storey
Journal of the American College of Cardiology|February 26, 2011
Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgeryRobert F Storey
Heart (British Cardiac Society)|March 20, 2021
Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continuesRobert F Storey
Current Pharmaceutical Design|April 14, 2006
Biology and pharmacology of the platelet P2Y12 receptorRobert F Storey
Thrombosis and Haemostasis|April 12, 2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitorsRobert F Storey
Lancet (London, England)|December 26, 2008
Clopidogrel in acute coronary syndrome: to genotype or not?Robert F Storey
Pageof 41

Showing results (1-10 of 401) with videos related to

Sort By:
Pageof 41
Postgraduate Medical Journal|December 22, 2011
Republished education in heart: New P2Y₁₂ inhibitorsRobert F Storey
European Heart Journal|May 7, 2015
More transparency for a therapeutic window in platelet P2Y12 inhibition?Robert F Storey
Clinical Medicine (London, England)|June 4, 2014
Beware the normal angiogramRobert F Storey
European Heart Journal|October 21, 2020
The long journey of individualizing antiplatelet therapy after acute coronary syndromesRobert F Storey
Circulation|February 20, 2024
Antiplatelet Therapy After PCI: The Art and Science of De-EscalationRobert F Storey
Journal of the American College of Cardiology|February 26, 2011
Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgeryRobert F Storey
Heart (British Cardiac Society)|March 20, 2021
Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continuesRobert F Storey
Current Pharmaceutical Design|April 14, 2006
Biology and pharmacology of the platelet P2Y12 receptorRobert F Storey
Thrombosis and Haemostasis|April 12, 2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitorsRobert F Storey
Lancet (London, England)|December 26, 2008
Clopidogrel in acute coronary syndrome: to genotype or not?Robert F Storey
Pageof 41